Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230040/S035

Cordella Pulmonary Artery Sensor System (CorPASS)

Endotronix, Inc. · Decision date Oct 20, 2026

MEDTECHLEDGER EXPLANATIONP230040/S035

What did the FDA decide?

The FDA recorded decision OK30 on 2026-10-20 for P230040/S035, a 30-Day Notice supplement to the Cordella Pulmonary Artery Sensor System (CorPASS) held by Endotronix, Inc. The supplement falls under the process change category for manufacturer, sterilizer, packager or supplier. The stated scope is removal of a redundant inspection process of the Coil PCB subassemblies. The device is listed in the implantable hemodynamic system category under the Cardiovascular specialty with product code MOM.

This action covers a manufacturing process change for a named subassembly rather than a new approval of the whole CorPASS system. The source record does not describe the inspection method removed, the rationale for treating it as redundant, or any verification data supporting the change; those details would sit in the supplement submission, which is not included here. No clinical, efficacy or patient-selection conclusions follow from this record, and the source gives no information on current labeling or post-change performance.

FDA approval order statement

removal of a redundant inspection process of the Coil PCB subassemblies
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 20, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230040/S035
Regulatory pathway
PMA supplement
Product code
MOM
Decision code
OK30
Decision date
Oct 20, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, hemodynamic, implantable.

Product code
MOM
FDA device class
3

For the original device and its historical approval scope, see PMA P230040. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230040 · Original PMA

    Cordella Pulmonary Artery Sensor System (CorPASS)

  2. P230040/S035 received

    Application receipt date recorded by FDA.

  3. P230040/S033 · Related supplement

    Cordella Pulmonary Artery Sensor System (CorPASS)

  4. P230040/S034 · Related supplement

    Cordella Pulmonary Artery Sensor System (CorPASS)

  5. P230040/S031 · Related supplement

    Cordelia Pulmonary Artery Pressure Sensor System (CorPASS)

  6. P230040/S035 · FDA decision

    30-Day Notice

  7. P230040/S030 · Related supplement

    Cordella Pulmonary Artery Sensor System

Timeline entries are records held by MedtechLedger for P230040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230040

Product / regulatory recordCompanyPathwayDecision dateSource
Endotronix, Inc.PMA approvalJun 20, 2024FDA
Endotronix, Inc.PMA supplementSep 25, 2026FDA
Endotronix, Inc.PMA supplementOct 14, 2026FDA
Endotronix, Inc.PMA supplementOct 16, 2026FDA
Endotronix, Inc.PMA supplementOct 29, 2026FDA

Explore the linked device profile

Other records with product code MOM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Endotronix, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1415 W. Diehl Rd., Suite 500w, Naperville, IL, 60563

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records